Nuwiq
Nuwiq 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hemophilia A。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
12 项
已进入 III/IV 期
41 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Emory University
- Bayer
- Shanghai Xinzhi BioMed Co., Ltd.
- Hoffmann-La Roche
- Octapharma
- Northwell Health
- Wayne State University
- Indiana Hemophilia &Thrombosis Center, Inc.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Brazil、加拿大、Colombia、丹麦、意大利、日本、Lithuania、Mexico、挪威、西班牙、中国
正在招募患者的 Nuwiq 研究
An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A
不适用招募中美国Brazil加拿大ColombiaNCT07088458Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
II 期 / III 期招募中中国NCT06111638A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
III 期招募中美国比利时加拿大ColombiaNCT06998524Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
不适用招募中美国ArgentinaAzerbaijanBelarusNCT03695978Treatment of Hemophilia A Patients With FVIII Inhibitors
不适用招募中美国德国NCT04023019Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
II 期招募中美国NCT07032792Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
IV 期招募中美国芬兰法国德国NCT05936580Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
不适用招募中美国NCT05022459Hemlibra in Mild Hemophilia A
IV 期招募中美国NCT04567511A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
III 期招募中美国Argentina奥地利BrazilNCT07416526Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
不适用招募中法国NCT07723560Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
IV 期招募中中国NCT06864975A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
I 期招募中美国加拿大NCT06349473A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD
III 期招募中加拿大NCT06205095Hemophilia A Research Program
不适用招募中美国NCT07414511Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome
不适用招募中瑞士NCT07400848Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
III 期招募中美国Argentina澳大利亚BrazilNCT05145127Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
不适用招募中德国NCT05802836Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
IV 期招募中美国Croatia芬兰法国NCT05935358A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
III 期招募中美国Argentina澳大利亚奥地利NCT05611801A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
III 期招募中中国NCT07129343Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
III 期招募中美国澳大利亚加拿大法国NCT05568719Von Willebrand Factor in Pregnancy (VIP) Study
不适用招募中美国NCT04146376TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
不适用招募中美国NCT07692217
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。